Clinical Trial Update: A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) [Phase 3]

View source ↗

Summary

A Phase 3 study compares deucravacitinib to placebo in active systemic lupus erythematosus. The trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Sotyktu (Deucravacitinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: ACTIVE_NOT_RECRUITING